ENSC

+ Watchlist + Portfolio

Ensysce Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.39
52-Week Range: $0.23 – $2.75
Market Cap: $7.35M
P/E (TTM): —
EPS (TTM): -2.56
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -1295.09%
Return on Assets: -185.51%
Gross Margin: -130.56%
Operating Margin: -221.28%
Profit Margin: -280.48%
Current Ratio: 0.70
Debt/Equity: —
Total Debt: $196.84K
Free Cash Flow: $-4.50M
Revenue Growth: -15.10%
Earnings Growth: —
Enterprise Value: $6.74M

ENSC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$19.84M	$7.59M	$7.22M	$10.38M
Selling, General & Admin	$6.91M	$5.36M	$4.72M	$4.93M
Operating Expenses	$24.22M	$10.72M	$6.73M	$10.24M
Operating Income	-$24.22M	-$10.72M	-$6.73M	-$10.24M
EBITDA	-$24.10M	-$10.27M	-$6.70M	-$10.15M
Pretax Income	-$24.21M	-$10.63M	-$7.99M	-$10.18M
Net Income	-$24.17M	-$10.61M	-$7.99M	-$10.18M
Diluted EPS	-2091.60	-70.40	-11.45	-3.98
Diluted Shares	35633	150937	1.36M	4.57M

ENSC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.15M	$1.12M	$3.50M	$4.31M
Receivables	$276.82K	$97.56K	$124.11K	$420.35K
Current Assets	$5.30M	$2.29M	$5.34M	$7.24M
Total Assets	$5.89M	$2.71M	$5.60M	$7.45M
Current Liabilities	$9.46M	$3.33M	$2.21M	$4.57M
Long-Term Debt	$140.15K	—	—	—
Total Debt	$4.43M	$854.70K	$301.66K	$306.71K
Total Liabilities	$9.91M	$3.36M	$2.22M	$4.57M
Retained Earnings	-$110.93M	-$121.56M	-$129.54M	-$139.72M
Shareholders' Equity	-$3.71M	-$322.86K	$3.71M	$3.21M
Working Capital	-$4.17M	-$1.04M	$3.14M	$2.67M
Net Debt	$1.26M	—	—	—

ENSC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.89M	-$10.78M	-$7.50M	-$7.81M
Capital Expenditure	—	—	—	-$123.64K
Free Cash Flow	-$17.89M	-$10.78M	-$7.50M	-$7.93M
Depreciation & Amortisation	$0.00	—	$0.00	$6.53K
Stock-Based Compensation	$1.07M	$879.16K	$110.72K	$177.09K
Investing Cash Flow	$4.50K	$0.00	$0.00	-$123.64K
Financing Cash Flow	$8.77M	$8.76M	$9.88M	$8.74M
Net Change in Cash	-$9.12M	-$2.02M	$2.38M	$808.28K

ENSC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.89M	$1.92M	$2.95M	$3.61M	$3.35M
Selling, General & Admin	$1.40M	$1.20M	$1.28M	$1.05M	$1.18M
Operating Expenses	$1.97M	$1.75M	$3.74M	$2.78M	$3.56M
Operating Income	-$1.97M	-$1.75M	-$3.74M	-$2.78M	-$3.56M
EBITDA	-$1.94M	-$1.73M	-$3.72M	-$2.76M	-$3.55M
Pretax Income	-$1.95M	-$1.73M	-$3.73M	-$2.77M	-$3.56M
Net Income	-$1.95M	-$1.73M	-$3.73M	-$2.77M	-$3.56M
Diluted EPS	-1.39	-0.79	-1.29	-0.75	-0.52
Diluted Shares	1.40M	2.20M	2.89M	3.69M	6.84M

ENSC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.05M	$2.21M	$1.67M	$4.31M	$745.48K
Receivables	$22.00K	$1.20M	$4.41K	$420.35K	$0.00
Current Assets	$4.40M	$5.28M	$2.93M	$7.24M	$2.01M
Total Assets	$4.61M	$5.57M	$3.18M	$7.45M	$2.17M
Current Liabilities	$1.76M	$2.51M	$2.30M	$4.57M	$2.84M
Total Debt	$257.38K	$424.52K	$387.70K	$306.71K	$245.85K
Total Liabilities	$1.89M	$2.51M	$2.30M	$4.57M	$2.84M
Retained Earnings	-$131.49M	-$133.22M	-$136.95M	-$139.72M	-$143.28M
Shareholders' Equity	$3.05M	$3.39M	$1.20M	$3.21M	-$340.04K
Working Capital	$2.64M	$2.77M	$623.55K	$2.67M	-$828.27K

ENSC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.71M	-$2.71M	-$1.87M	-$1.53M	-$3.50M
Free Cash Flow	-$1.71M	-$2.71M	-$1.99M	-$1.53M	-$3.50M
Depreciation & Amortisation	$0.00	—	—	—	$6.53K
Stock-Based Compensation	$16.25K	$90.64K	$45.86K	$24.34K	$8.74K
Investing Cash Flow	—	—	—	$0.00	—
Financing Cash Flow	$1.26M	$1.87M	$1.45M	$4.16M	-$63.95K
Net Change in Cash	-$449.59K	-$840.92K	-$538.36K	$2.64M	-$3.56M

Market Snapshot

About

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing safer prescription drugs using its proprietary technology platforms. The company's Trypsin-Activated Abuse Protection (TAAP) platform is designed to prevent opioid abuse while maintaining pain relief efficacy. Ensysce is also developing overdose protection technology (MPAR) that can slow or stop drug release in overdose situations. The company's pipeline focuses on addressing the opioid crisis through abuse-deterrent and overdose-resistant formulations.